MedTrace Logo

Ticagrelor vs. Prasugrel Effects on Infarct Size

NCT02507323 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-05-04

No results posted yet for this study

Summary

This study has been designed as a randomized, double-blind trial to provide definitive evidence on the effects of ticagrelor and prasugrel on myocardial salvage in patients with anterior ST Segment Elevation Myocardial Infarction (STEMI) undergoing primary Percutaneous Coronary Intervention (PCI). This study will also measure the effects of ticagrelor vs. prasugrel on secondary endpoints listed above. This study design aims to test the hypothesis that ticagrelor will reduce myocardial infarct size as a proportion of the ischemic area at risk when compared to prasugrel.

Conditions

Interventions

DRUG

ticagrelor

A platelet aggregation inhibitor

DRUG

prasugrel

a thienopyridine class inhibitor of platelet activation and aggregation

DRUG

Placebo

placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Yochai Birnbaum

    lead OTHER

Principal Investigators

  • Yochai Birnbaum, MD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-08-31
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02507323 on ClinicalTrials.gov